Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTC-STOP Trial
ISRCTN82499869Phase 3Terminated
- Sponsor
- The Institute of Cancer Research
- Start
- Jan 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of docetaxel and cabazitaxel in prostate cancer (PCa) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Overall survival. Started Jan 2017; status: terminated.
02
Drugs
docetaxelcabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ISRCTN82499869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82499869.